[1] |
丁惠国, 屠红, 曲春枫, 等. 原发性肝癌的分层筛查与监测指南(2020版)[J]. 临床肝胆病杂志, 2021, 37(2): 286-295.
|
|
DING H G, TU H, QU C F, et al. Guideline for stratified screening and surveillance of primary liver cancer (2020 edition)[J]. J Clin Hepatol, 2021, 37(2): 286-295.
|
[2] |
HU K S, LU S X, LI M, et al. A novel pre-treatment model predicting risk of developing refractoriness to transarterial chemoembolization in unresectable hepatocellular carcinoma[J]. J Cancer, 2020, 11(15): 4589-4596.
doi: 10.7150/jca.44847
pmid: 32489476
|
[3] |
XIE D Y, REN Z G, ZHOU J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463.
doi: 10.21037/hbsn-20-480
|
[4] |
SCHMITZ S U, GROTE P, HERRMANN B G. Mechanisms of long noncoding RNA function in development and disease[J]. Cell Mol Life Sci, 2016, 73(13): 2491-2509.
doi: 10.1007/s00018-016-2174-5
pmid: 27007508
|
[5] |
YIN X, ZHENG S S, ZHANG L, et al. Identification of long noncoding RNA expression profile in oxaliplatin-resistant hepatocellular carcinoma cells[J]. Gene, 2017, 596: 53-88.
doi: S0378-1119(16)30803-4
pmid: 27729273
|
[6] |
SHI X B, LI Y, SUN Y C, et al. Genome-wide analysis of lncRNAs, miRNAs, and mRNAs forming a prognostic scoring system in esophageal squamous cell carcinoma[J]. PeerJ, 2020, 8: e8368.
doi: 10.7717/peerj.8368
|
[7] |
HE Y K, YE Y F, TIAN W, et al. A novel lncRNA panel related to ferroptosis, tumor progression, and microenvironment is a robust prognostic indicator for glioma patients[J]. Front Cell Dev Biol, 2021, 9: 788451.
doi: 10.3389/fcell.2021.788451
|
[8] |
WANG Y C, HU B H, ZHANG W W, et al. Linc00601 upregulation promotes hepatocellular carcinoma development by activating MAPK signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(11): 6039-6045.
|
[9] |
RIDDELL I A. Cisplatin and oxaliplatin: our current understanding of their actions[J]. Met Ions Life Sci, 2018, 18: /books/9783110470734/9783110470734-007/9783110470734-007.xml.
|
[10] |
曹宇, 倪娟, 曹能, 等. Gadd45蛋白家族在肿瘤发生、发展中的作用[J]. 肿瘤防治研究, 2019, 46(3): 271-274.
|
|
CAO Y, NI J, CAO N, et al. Role of Gadd45 protein family in tumorigenesis and development[J]. Cancer Res Prev Treat, 2019, 46(3): 271-274.
|
[11] |
FENG X M, LIU H, ZHANG Z J, et al. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells[J]. J Exp Clin Cancer Res, 2017, 36(1): 123.
doi: 10.1186/s13046-017-0594-1
|
[12] |
LI J H, XIE X Y, ZHANG L, et al. Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(13): 3970-3977.
doi: 10.3748/wjg.v21.i13.3970
|
[13] |
GAO S, ZHANG P J, GUO J H, et al. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients[J]. World J Gastroenterol, 2015, 21(36): 10443-10452.
doi: 10.3748/wjg.v21.i36.10443
|
[14] |
MARTINEZ-BALIBREA E, MARTÍNEZ-CARDÚS A, GINÉS A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance[J]. Mol Cancer Ther, 2015, 14(8): 1767-1776.
doi: 10.1158/1535-7163.MCT-14-0636
|
[15] |
LIM L J, WONG S Y S, HUANG F Y, et al. Roles and regulation of long noncoding RNAs in hepatocellular carcinoma[J]. Cancer Res, 2019, 79(20): 5131-5139.
doi: 10.1158/0008-5472.CAN-19-0255
pmid: 31337653
|
[16] |
HUANG H, CHEN J, DING C M, et al. LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363[J]. J Cell Mol Med, 2018, 22(6): 3238-3245.
doi: 10.1111/jcmm.13605
pmid: 29602203
|
[17] |
HU H Q, YANG L, LI L J, et al. Long non-coding RNA KCNQ1OT1 modulates oxaliplatin resistance in hepatocellular carcinoma through miR-7-5p/ABCC1 axis[J]. Biochem Biophys Res Commun, 2018, 503(4): 2400-2406.
doi: 10.1016/j.bbrc.2018.06.168
|
[18] |
DONG S B, FU Y, YANG K B, et al. Linc01559 served as a potential oncogene and promoted resistance of hepatocellular carcinoma to oxaliplatin by directly sponging miR-6783-3p[J]. Anticancer Agents Med Chem, 2021, 21(2): 278-286.
doi: 10.2174/1871520620666200721122317
|
[19] |
HUANG G L, LI L, LIANG C Y, et al. Upregulated UCA1 contributes to oxaliplatin resistance of hepatocellular carcinoma through inhibition of miR-138-5p and activation of AKT/mTOR signaling pathway[J]. Pharmacol Res Perspect, 2021, 9(1): e00720.
|
[20] |
XIONG H, NI Z, HE J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells[J]. Oncogene, 2017, 36(25): 3528-3540.
doi: 10.1038/onc.2016.521
pmid: 28166203
|
[21] |
ZHU N, SHAO Y, XU L, et al. Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells[J]. Mol Biol Rep, 2009, 36(8): 2075-2085.
doi: 10.1007/s11033-008-9419-9
pmid: 19048389
|
[22] |
TONG T, JI J F, JIN S Q, et al. Gadd45a expression induces Bim dissociation from the cytoskeleton and translocation to mitochondria[J]. Mol Cell Biol, 2005, 25(11): 4488-4500.
pmid: 15899854
|
[23] |
DU K G, LU F, XIE C Z, et al. Toxoplasma gondii infection induces cell apoptosis via multiple pathways revealed by transcriptome analysis[J]. J Zhejiang Univ Sci B, 2022, 23(4): 315-327.
doi: 10.1631/jzus.B2100877
|
[24] |
JANG H J, YANG J H, HONG E, et al. Chelidonine induces apoptosis via GADD45a-p53 regulation in human pancreatic cancer cells[J]. Integr Cancer Ther, 2021, 20: 15347354211006191.
|
[25] |
WANG X, ZOU F, ZHONG J T, et al. Secretory clusterin mediates oxaliplatin resistance via the Gadd45a/PI3K/Akt signaling pathway in hepatocellular carcinoma[J]. J Cancer, 2018, 9(8): 1403-1413.
doi: 10.7150/jca.23849
pmid: 29721050
|